@article{5864e8cb73944cf5adb3acef3356a09d,
title = "Global Survey of Guidelines for the Management of Epilepsy in Pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy",
abstract = "The ILAE Task Force on Women and Pregnancy conducted a survey among ILAE Chapters of their use of guidelines or recommendations for the management of women with epilepsy during pregnancy. A web-based questionnaire including 10 questions was sent to the 118 ILAE Chapters in December 2017 with repeated reminders until the end of February 2018. In total, 77 chapters (65%) responded, although not to all questions. Out of those responding, 68% reported having guidelines or recommendations, 34% of which were from 2014 or earlier. At least 20% of the guidelines did not include information on possible risk to cognitive development, information regarding specific risks with specific antiepileptic drugs, nor recommendations regarding selection of antiepileptic drugs. Among those responding to the question, 91% reported that recommendations were made regarding folate supplementation, but the recommended dose ranged from 0.4 mg/d to 4 mg/d or more; 34% did not include recommendations regarding drug level monitoring during pregnancy, and 19% did not include guidelines on breastfeeding. Our survey demonstrates that there is a need for the development of up-to-date, globally applicable recommendations for the management of epilepsy during pregnancy.",
keywords = "epilepsy, guidelines, pregnancy, survey",
author = "Torbj{\"o}rn Tomson and Dina Battino and Rebecca Bromley and Silvia Kochen and Meador, {Kimford J.} and Pennell, {Page B.} and Thomas, {Sanjeev V.}",
note = "Funding Information: KM is funded by NIH NINDS, NICHD #2U01‐NS038455 and has also received research support from Sunovion Pharmaceuticals, and travel support from Eisai. The Epilepsy Study Consortium pays Dr Meador's university for his research consultant time related to Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher‐Smith Laboratories, and UCB Pharma. PBP is funded by NIH NINDS, NICHD #2U01‐NS038455 and has also received research support from Epilepsy Foundation, and honoraria and travel support from American Epilepsy Society, American Academy of Neurology, Epilepsy Foundation, National Institutes of Health, and academic institutions for CME lectures. RB is funded by a National Institute for Health Research grant (PDF‐2013‐06‐041). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. RB has received a consultancy fee from UCB Pharma on one occasion, for a matter unrelated to this subject area. Publisher Copyright: {\textcopyright} 2020 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/epi4.12420",
language = "English",
volume = "5",
pages = "366--370",
journal = "Epilepsia Open",
issn = "2470-9239",
publisher = "wiley",
number = "3",
}